Childhood cancers trials in Germany

In Germany 143 Also abroad 2481

143 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Brunswick, Chemnitz, Duesseldorf, Hamburg, Heidelberg, Herne, Jena, Leipzig, Minden, Stuttgart, Tuebingen
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Not yet taking people in Germany
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
Where
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Cologne, Dortmund, Duesseldorf, Duisburg, Erfurt, Erlangen, Essen, Freiburg im Breisgau, Goettingen, Halle (Saale), Hamburg, Hanover, Heidelberg, Karlsruhe, Kassel, Kiel, Krefeld, Leipzig, Luebeck, Mainz, Minden, Regensburg, Rostock, Stuttgart, Tuebingen, Ulm
Age
Up to 5 years
People
96 worldwide
Run by
Nationwide Children's Hospital
See details and how to joinNCT07291102 · EU 2024-517133-40-00
Phase 2/3Taking people
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Where
Frankfurt
Age
3 months to 25 years
People
1,000 worldwide
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT07297914 · EU 2025-522052-13-00
Phase 3Taking people
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
Where
Aachen, Augsburg, Bad Saarow, Berlin, Bielefeld, Bonn, Bremen, Brunswick, Chemnitz, Cologne, Cottbus, Datteln, Dortmund, Dresden, Duesseldorf, Erfurt, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Gießen, Goettingen, Greifswald, Halle Saale, Hamburg, Hanover, Heidelberg, Herdecke, Homburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Krefeld, Leipzig, Lübeck, Magdeburg, Mainz, Mannheim, Minden, Muenster, München, Munich, Nuremberg, Nürnberg, Oldenburg, Regensburg, Rostock, Sankt Augustin, Schwerin, Stuttgart, Tuebingen, Ulm, Wuerzburg
Age
Up to 64 years
People
1,351 worldwide
Run by
GPOH gGmbH
See details and how to join2022-501180-40-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Aachen, Augsburg, Berlin, Bonn, Bremen, Cologne, Dortmund, Dresden, Duesseldorf, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Halle Saale, Hamburg, Hanover, Heidelberg, Kiel, Krefeld, Mainz, Muenster, Munich, Stuttgart, Tuebingen, Ulm
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 3Not yet taking people in Germany
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
Where
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Bremen, Cologne, Dortmund, Dresden, Erfurt, Erlangen, Giessen, Goettingen, Halle (Saale), Jena, Karlsruhe, Kassel, Krefeld, Leipzig, Magdeburg, Mainz, Mannheim, Muenster, Regensburg, Sankt Augustin, Stuttgart, Wuerzburg
Age
Up to 64 years
People
231
Run by
University Of Cologne
See details and how to join2024-517295-37-00
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Berlin, Cologne, Duesseldorf, Essen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Kiel, Muenster, Munich, Wuerzburg
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Phase 1/2Taking people
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Where
Berlin, Cologne, Erlangen, Würzburg
Age
12 years and over
People
161 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00
Phase 1Taking people
A study of Mirdametinib in Infants and Toddlers under 24months of age with Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PNs)
Where
Cologne, Hamburg
Age
Up to 17 years
People
8 worldwide
Run by
Merck Healthcare KGaA
See details and how to join2025-522000-24-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Hamburg, Leipzig, Mainz, Ulm
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1/2Taking people
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Where
Berlin, Cologne, Erlangen, Goettingen, Muenster, Munich, Tuebingen, Wuerzburg
People
40
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT06508775 · EU 2022-501648-14-00
Phase 1/2Not yet taking people in Germany
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
Where
Berlin, Cologne, Erlangen, Essen, Frankfurt Am Main, Hamburg
Age
Up to 64 years
People
22 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522019-40-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Berlin, Buxtehude, Dresden, Erfurt, Erlangen, Gera, Halle (Saale), Hamburg, Kiel, Leipzig, Ludwigshafen Am Rhein, Luebeck, Magdeburg, Mainz, Mannheim, Marburg, Minden, Muenster, Nuremberg, Tuebingen, Wuerzburg
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 1/2Taking people
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Where
Berlin, Cologne, Giessen, Muenster, Tuebingen
Age
1 month to 17 years
People
50 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
No phaseTaking people
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Where
Freiburg im Breisgau
People
170 worldwide
Run by
Chiesi Farmaceutici S.p.A.
See details and how to joinNCT06423573
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
Cologne
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 2Taking people
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Where
Berlin, Duesseldorf, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Hamburg, Hanover, Jena, Kiel, Muenster, Tuebingen, Ulm, Wuerzburg
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00
Phase 1Taking people
Long-term follow-up of patients treated with GD2IL18CART
Where
Erlangen, Essen, Muenster, Tuebingen
People
20
Run by
Universitaet Muenster
See details and how to join2025-521497-34-00
Phase 2Enrolling by invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Where
Dresden, Hamburg, Heidelberg, Mainz, Munich, Wuerzburg
People
1,500 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT05041309 · EU 2023-507041-28-00
Phase 3Taking people
An international trial for children with atypical teratoid/rhabdoid tumours (ATRT)
Where
Aachen, Augsburg, Berlin, Bonn, Cologne, Dresden, Erlangen, Essen, Frankfurt Am Main, Gießen, Göttingen, Halle Saale, Hamburg, Hanover, Heidelberg, Jena, Kassel, Kiel, Leipzig, Magdeburg, Mainz, Muenster, Munich, Ratisbon, Tuebingen, Ulm, Wuerzburg
Age
Up to 17 years
People
301 worldwide
Run by
GPOH gGmbH
See details and how to join2022-501456-28-00
Phase 3Not yet taking people in Germany
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
Where
Aachen, Augsburg, Berlin, Brunswick, Chemnitz, Cologne, Cottbus, Dortmund, Dresden, Duesseldorf, Erfurt, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Goettingen, Greifswald, Halle (Saale), Hanover, Heidelberg, Heilbronn, Herdecke, Homburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Leipzig, Luebeck, Magdeburg, Mannheim, Minden, Muenster, Munich, Nuernberg, Oldenburg, Regensburg, Rostock, Sankt Augustin, Schwerin, Stuttgart, Tuebingen, Ulm, Witten, Wolfsburg, Wuerzburg
Age
Up to 17 years
People
2,250
Run by
Universitaetsklinikum Schleswig-Holstein AöR
See details and how to join2025-522190-11-01
Phase 1Taking people
Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
Where
Tübingen
Age
12 years and over
People
20
Run by
University Hospital Tuebingen
See details and how to joinNCT06789198 · EU 2024-519387-41-00
Phase 3Taking people
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Where
Erlangen, Essen, Munich
Age
12 years to 100 years
People
240 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00
No phaseTaking people
Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.
Where
Berlin, Bonn, Cologne, Essen, Frankfurt, Hamburg, Jena, Mainz, München, Nuremberg, Stuttgart, Ulm
Age
3 years to 18 years
People
346
Run by
Universität Duisburg-Essen
See details and how to joinNCT07647471